Post-finasteride syndrome: a surmountable challenge for clinicians

Traish, Abdulmaged M.

doi:10.1016/j.fertnstert.2019.11.030

Cited by 72 publications

(73 citation statements)

References 198 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gur et al [30] report instead that the true prevalence of sexual side effects with 5-ARI treatment is currently unknown. (D) There have been recent reports of persistent sexual dysfunction after discontinuation of finasteride treatment [32,56,60,97,99,100,129,131,134,141,147,149,166,170,237]. Several authors have considered gynecomastia as a sexual dysfunction.…”

Section: Dutasteride (A) (B) (C) Finasteride (A) (B) (C) (D)mentioning

confidence: 99%

Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors

Torre

Palleria

Tamanini

et al. 2021

Uro

View full text Add to dashboard Cite

This is a critical review of the current literature data about sexual dysfunction as a potential side effect related to drugs commonly used for the treatment of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms. In this narrative review, we analyzed data from the literature related to the development of sexual dysfunctions during the treatment of BPH or LUTS. Both α-blockers and 5-alpha reductase inhibitors (5-ARIs) can induce erectile dysfunction, ejaculatory disorders and a reduction in sexual desire. The sexual side effect profile of these drugs is different. Among the α-blockers, silodosin appears to have the highest incidence of ejaculatory disorders. Persistent sexual side effects after the discontinuation of finasteride have been recently reported; however, further studies are needed to clarify the true incidence and the significance of this finding. However, most of the published studies are affected by a weak methodology and other important limitations, with only a few RCTs available. Therefore, it is desirable that future studies will include validated tools to assess and diagnose the sexual dysfunction induced by these medications, especially for ejaculation and sexual desire disorders.

show abstract

Section: Dutasteride (A) (B) (C) Finasteride (A) (B) (C) (D)mentioning

confidence: 99%

Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors

Torre

Palleria

Tamanini

et al. 2021

Uro

View full text Add to dashboard Cite

show abstract

“…Although clinically effective against pattern hair loss in statistically significant cohort trials, the published literature also reports serious negative side effects that appear to persist even after discontinuation of the drug. These side effects include loss of libido, ejaculatory dysfunction, disorders of the penis and testes, gynecomastia, and cognitive symptoms including suicidal ideation [16].…”

Section: Minoxidilmentioning

confidence: 99%

An Uncontrolled Case Series Using a Botanically Derived, β-Cyclodextrin Inclusion Complex in Two Androgenetic Alopecia-Affected Male Subjects

Marcovici

Bauman²

2020

Cosmetics

View full text Add to dashboard Cite

Drug-based monotherapy provides limited clinical benefits in polygenic disorders, such as androgenetic alopecia. Possible benefits must be measured against non-trivial risks of negative side effects. Several well-controlled, peer-reviewed, basic science studies have demonstrated novel mechanisms of action and potential utility for natural-based phytochemicals in the treatment of androgen-mediated disorders, including androgenetic alopecia. Yet, due to phytochemical instability, volatility, and incompatibility, the bridge from in vitro potential to clinical efficacy remains largely unmet. Recent advances in nanomaterial manipulation provide enhanced platforms, such as cyclodextrins, in which these phytochemicals may be enveloped and delivered without triggering the loss of intended function. Unexpected, positive results of an uncontrolled case series for a cyclodextrin-enabled, natural-based formula containing γ linolenic acid, β-Sitosterol, epigallocatechin gallate, and genistein, administered concomitantly via oral and topical form in two androgenetic alopecia-affected, male subjects over the course of 270 days were found. At baseline, significant baldness in the vertex scalp of both subjects was observed. Subsequent 90-day time points demonstrated marked hair thickening. On treatment day 270 (conclusion), scalp hair loss was no longer evident in either patient. Particularly in the setting of a disorders, such as androgenetic alopecia, nano-complexed, botanically-based compositions may offer beneficial adjunctives or alternatives to traditional drug-based/surgical medical treatments.

show abstract

“…Hair loss treatments using Food and Drug Administration-approved medications like minoxidil and finasteride impose several side effects [13][14][15][16][17][18]. Therefore, natural substances as alternatives and safe substitutes have garnered research interest.…”

Section: Introductionmentioning

confidence: 99%

Treatment with <em>Malva verticillata</em> Seed Extracts Alleviates Alopecia via Activation of Wnt/β-catenin Signaling

Ryu¹,

Ji-Yeon²,

Lee³

et al. 2020

Preprint

View full text Add to dashboard Cite

Hair loss attributed to excessive stress from work and lifestyle changes has become a growing concern, particularly among young individuals. However, currently used drugs such as minoxidil and finasteride impose a plethora of side effects. Therefore, natural substances as alternatives have garnered research interest. A recent study showed the efficacy of Malva verticillata seed extracts in alleviating hair loss via upregulation of the Wnt/β-catenin signaling pathway. In this study, the efficacy of M. verticillata seed extracts on alleviation of hair loss was further investigated. Further fractionation and purification of the seed extracts using silica gel column chromatography and preparative high-performance liquid chromatography helped identify linoleic acid (LA) and oleic acid as the major bioactive components. LA insufficiency is reported to cause hair loss. However, its mechanism of action is not clearly known. Here, we explored the efficacy of LA treatment on preventing hair loss and its underlying mechanism of action. We found that LA treatment activated Wnt/β-catenin signaling and induced dermal papilla cell (DPC) proliferation in cell proliferation assays. Moreover, it increased the expression of cell cycle proteins such as cyclin D1 and cyclin-dependent kinase 2. LA treatment also increased the expression of vascular endothelial growth factor, insulin-like growth factor-1, hepatocyte growth factor, and keratinocyte growth factor in a concentration-dependent manner and significantly inhibited that of DKK-1, induced by dihydrotestosterone. These findings suggest that LA treatment induces hair growth by increasing DPC proliferation and alleviates androgenic alopecia by activating Wnt/β-catenin signaling in DPCs.

show abstract

Post-finasteride syndrome: a surmountable challenge for clinicians

Cited by 72 publications

References 198 publications

Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors

Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors

An Uncontrolled Case Series Using a Botanically Derived, β-Cyclodextrin Inclusion Complex in Two Androgenetic Alopecia-Affected Male Subjects

Treatment with <em>Malva verticillata</em> Seed Extracts Alleviates Alopecia via Activation of Wnt/β-catenin Signaling

Contact Info

Product

Resources

About